Teams hyper-focus on replicating process parameters during tech transfer, but this is a blind spot. The true measure of success is a statistically powerful analytical and sampling plan that rigorously proves the process transferred successfully and can detect any deviations.

At Rainbird, engineers build the first 'production intent' units for field trials themselves, on the actual assembly line. This serves two critical functions: it produces the necessary test units and simultaneously allows the engineering team to validate and debug the manufacturing process before scaling up.

When scaling to production, the biggest pitfall is the implicit knowledge held by the original design team who unconsciously fill procedural gaps. To succeed, involve someone with a manufacturing background but no project history to rigorously review procedures and expose these unstated assumptions before scaling.

Instead of immediately scaling up the manufacturing process between clinical Phase 1 and 2, it is strategically better to produce more batches using the established Phase 1 process. This approach builds critical knowledge about process parameters and CQAs through repetition and increased clinical exposure.

To drive a production-focused culture in R&D, implement a daily "shift pass-down" report. This manufacturing practice forces the team to document what they accomplished versus what they planned, and explain the deltas. It brings factory-floor accountability and rigor to the traditionally less structured R&D process.

To ensure a smooth transition from development to production, an operations or manufacturing SME must be part of the design process from the start. Otherwise, products are developed without manufacturability in mind, leading to expensive, reactive fixes and subjective quality control during scale-up.

A process that seems simple in a development lab is often not viable in a strict GMP manufacturing environment. To create truly manufacturable therapies, process development scientists need direct, hands-on exposure to GMP constraints and workflows to avoid significant rework and delays.

The trade-off between speed and process robustness is a false dichotomy. The key is to design a robust process that includes predefined and validated "pause steps." These holding points allow for flexibility to handle unforeseen issues like mechanical failures without compromising the entire batch, thus enabling both speed and quality.

In bioprocessing, it is more efficient to design a development process that accommodates the constraints of the manufacturing facility. Forcing a plant to adapt to a rigid process is difficult and costly. This includes making early, scalable choices about materials like chromatography resins to ensure a smooth tech transfer.